

- *Lists presented for the appointment of the board of directors and the board of statutory auditors*
- *Extended deadline for the submission of lists for the board of statutory auditors*

Milan (Italy), 25 March 2016 – With reference to the shareholders' meeting of MolMed S.p.A. (MLM.MI), convened for 18 April 2016 on single call to decide, among other items, on the appointment of members of the board of directors and of the board of statutory auditors, MolMed announces that on expiry of the deadline of 24 March 2016, the shareholder Fininvest S.p.A. - who certified the ownership of 25,43% of the ordinary shares of the Company, submitted the following lists for the renewal of the corporate bodies.

List for the appointment of the board of directors

NR	OFFICE	CANDIDATE
1	Presidente	Claudio Bordignon
2	Consigliere	Riccardo Palmisano
3	Consigliere	Alfredo Messina
4	Consigliere	Alberto Luigi Carletti
5	Consigliere	Laura Iris Ferro (*)
6	Consigliere	Sabina Grossi
7	Consigliere	Carlo Incerti (*)
8	Consigliere	Elisabeth Robinson (*)
9	Consigliere	Mario Masciocchi (*)
10	Consigliere	Didier Trono (*)
11	Consigliere	Raffaella Ruggiero (*)

(*) Candidates who stated to qualify as independent directors

List for the appointment of the board of statutory auditors

NR	OFFICE	CANDIDATE
1	Chairman	Riccardo Perotta
2	Auditor	Flavia Daunia Minutillo
3	Auditor	Enrico Scio
4	Substitute	Alessia Bastiani
5	Substitute	Giuliana Maria Converti

The lists, including *curricula vitae* and statements of each candidate accepting the nomination and certifying that he/she meets the requirements of the law, are available (in Italian) to the public at MolMed's registered office, in the authorised storage system 1Info (www.1info.it) and on the Company's website (www.molmed.com) within the page devoted to the shareholders' meeting of 18 April 2016.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
 info@molmed.com - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

Extended deadline for the submission of other lists for the board of statutory auditors

On expiry of the deadline, only one list was filed for the appointment of the board of statutory auditors. Therefore, pursuant to Article 144-sexies, paragraph 5 of the Italian Issuers Regulation, the deadline for the submission of other lists for the board of statutory auditors - with the same procedures and enclosed documentation reported in the Notice published on 8 March 2016 on MolMed's website (www.molmed.com) - is extended to 27 March 2016, and the minimum threshold necessary for presenting a list is reduced by half.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and secondary office at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations Director

MolMed S.p.A.

telefono: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com